Myricitrin did not significantly increase BrdU incorporation in primary rat skeletal muscle satellite-cell cultures at 25 or 100 nM. Casuarinin and the HGF positive control increased incorporation in the same experiment. The lemon myrtle extract’s satellite-cell activation therefore cannot be assigned to myricitrin on these results. [1]
In C2C12 cultures exposed to 100 mM glucose for 48 h, myricitrin produced concentration-dependent redox-marker changes. SOD increased at 1 μM and MDA decreased at 3 μM relative to untreated high glucose. At 10 μM, SOD instead decreased further and MDA remained above the normal-glucose control. CAT increased at all three concentrations. The mixed response limits a general claim of antioxidant protection. [2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
No significant stimulation of rat satellite-cell BrdU incorporation
Cell-based study · Primary skeletal muscle satellite-cell cultures isolated from male Sprague-Dawley rats over 6 months old [1]
Myricitrin at 25 and 100 nM did not significantly promote BrdU incorporation relative to control medium. Casuarinin and the HGF positive control were active in the same comparison. This is a model- and concentration-specific negative finding; it does not establish general inactivity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 25 and 100 nM
- Exposure duration
- 22 h sample incubation followed by a 2 h BrdU pulse
- Method
- Addition to 10% horse-serum DMEM; 10 μM BrdU pulse
- Vehicle
- Samples were dissolved in water or DMSO before dilution into medium; compound-specific choice and final DMSO percentage are not specified. Control was 10% horse-serum DMEM.
- Reported limits
- Purchased myricitrin catalog number, lot, purity and compound-specific stock solvent are not supplied in the relevant methods.
Methods and source locations
Compound reported in the paper: Myricitrin; Compound label in the paper: Myricitrin (Adooq Bioscience)
Reported myricitrin comparison only; extract and casuarinin activity must not be attributed to myricitrin or to a current Adooq lot.
Methods 2.2–2.5 and 2.10; Results 3.3; Figure 3a and caption
BrdU-positive satellite cells as a fraction of total satellite cells, expressed as fold change versus control: BrdU immunocytochemistry and microscopic cell counting; Figure 3 caption: mean ± SD, three independent cultures for each compound condition; control and HGF have nine independent cultures. One-way ANOVA with Dunnett’s multiple comparison test. — Methods 2.2–2.5 and 2.10; Results 3.3; Figure 3a and caption
Concentration-dependent redox-marker responses in high-glucose C2C12 cultures
Cell-based study · Mouse skeletal muscle C2C12 cultures exposed to 100 mM D-glucose; 5 mM D-glucose control [2]
Over 48 h, the reported marker response depended on concentration: 1 μM increased SOD and 3 μM lowered MDA, whereas 10 μM further decreased SOD relative to untreated high glucose. CAT rose at all tested concentrations. These are biochemical readouts from a cellular experiment, not proof of a direct molecular target or uniform cytoprotection.
Literature-Reported Treatment Conditions
- Treatment concentration
- Myricitrin 1, 3 or 10 μM with D-glucose 100 mM; untreated high-glucose comparator and 5 mM glucose control
- Exposure duration
- 48 h concurrent exposure
- Method
- Addition to C2C12 culture medium
- Co-treatment
- Concurrent high-glucose challenge; no second therapeutic compound
- Reported limits
- Myricitrin stock solvent/final vehicle, lot, purity and an osmolarity-matched control are not specified in the reviewed methods. Differentiation conditions are not described, despite use of both myoblast and myotube terminology. The independence level of reported n = 3 is not explained.
Methods and source locations
Compound reported in the paper: Myricitrin; Compound label in the paper: Myricitrin (AvaChem Scientific)
Reported C2C12 high-glucose marker comparisons only; no inference about direct PKC/NO inhibition, clinical efficacy, or current Adooq lot performance.
Methods: Materials, Cell culture, Experimental design, Lipid peroxidation and antioxidants enzyme measurements, Statistical assessment; Results: antioxidant defense; Figure 1a–d and caption
Malondialdehyde (MDA): Commercial assays on cell-homogenate supernatants (MDA, CAT and TAC: Zellbio; SOD: Randox). Mean ± SEM; reported n = 3 per group. One-way ANOVA followed by least significant difference tests. Absolute concentrations are not reconstructed from the plotted bars. — Methods: Materials, Cell culture, Experimental design, Lipid peroxidation and antioxidants enzyme measurements, Statistical assessment; Results: antioxidant defense; Figure 1a–d and caption
Superoxide dismutase (SOD): Commercial assays on cell-homogenate supernatants (MDA, CAT and TAC: Zellbio; SOD: Randox). Mean ± SEM; reported n = 3 per group. One-way ANOVA followed by least significant difference tests. Absolute concentrations are not reconstructed from the plotted bars. — Methods: Materials, Cell culture, Experimental design, Lipid peroxidation and antioxidants enzyme measurements, Statistical assessment; Results: antioxidant defense; Figure 1a–d and caption
Catalase (CAT) and total antioxidant capacity (TAC): Commercial assays on cell-homogenate supernatants (MDA, CAT and TAC: Zellbio; SOD: Randox). Mean ± SEM; reported n = 3 per group. One-way ANOVA followed by least significant difference tests. Absolute concentrations are not reconstructed from the plotted bars. — Methods: Materials, Cell culture, Experimental design, Lipid peroxidation and antioxidants enzyme measurements, Statistical assessment; Results: antioxidant defense; Figure 1a–d and caption